Erivedge: new skin cancer drug and first Hedgehog pathway inhibitor

Erivedge (vismodegib) has been launched by Roche for the treatment of advanced basal cell carcinoma (BCC).

Erivedge (vismodegib) is administered once daily until disease progression or unacceptable toxicity occurs.
Erivedge (vismodegib) is administered once daily until disease progression or unacceptable toxicity occurs.


Vismodegib inhibits the Hedgehog signalling pathway by binding to the Smoothened transmembrane protein. This prevents the activation and nuclear localisation of glioma-associated oncogene transcription factors and the induction of Hedgehog target genes, which are involved in abnormal cell proliferation, survival and differentiation in BCC.1


In the pivotal single-arm ERIVANCE BCC trial, patients with metastatic (n=33) or locally advanced (n=63) BCC were treated with oral daily dosing of 150mg vismodegib. Patients received treatment until disease progression, unacceptable toxic effects or discontinuation of the study.1,2

The primary endpoint was objective response rate defined as complete or partial response on two consecutive assessments separated by at least 4 weeks. Locally advanced patients were considered to have responded to treatment if a reduction of at least 30% in tumour size was observed. In the metastatic disease group, response was assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST).1,2

Efficacy data

Overall, 30% (95% CI 16-48%) of patients with metastatic disease and 43% (95% CI 31-56%) of those with locally advanced disease responded to treatment, exceeding the hypothesized percentages of 10% and 20%, respectively (p<0.001). The median duration of progression-free survival in both groups was 9.5 months.2

Teratogenic risk

A pregnancy prevention plan is in place for vismodegib owing to its teratogenic risk. Women of childbearing potential must meet the criteria set out in the plan and men and women being treated with vismodegib must use adequate contraception during and after therapy.1

Safety profile

The most commonly reported adverse events were muscle spasm, alopecia, dysgeusia, weight loss and fatigue.1,2


  1. Erivedge Summary of Product Characteristics, July 2013.
  2. Sekulic A et al. N Engl J Med 2012; 366: 2171–9.

View Erivedge drug record

Further information: Roche

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...

Purple, orange, blue and yellow blood test tubes on a tray.

New advice on vitamin B12 monitoring in patients taking metformin

Patients on metformin treatment with risk factors for...